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Abstract
The multifaceted oncogene c-Myc plays important roles in the development and progression of 
human cancer. Recent in vitro and in vivo studies have shown that the p19Arf–Mdm2–p53 and the 
ribosomal protein (RP)–Mdm2–p53 pathways are both essential in preventing oncogenic c-Myc-
induced tumorigenesis. Disruption of each pathway individually by p19Arf deletion or by 
Mdm2C305F mutation, which disrupts RP-Mdm2 binding, accelerates Eμ-myc transgene-induced 
pre-B/B-cell lymphoma in mice at seemingly similar paces with median survival around 10 and 11 
weeks, respectively, compared to 20 weeks for Eμ-myc transgenic mice. Because p19Arf can 
inhibit ribosomal biogenesis through its interaction with nucleophosmin (NPM/B23), RNA 
helicase DDX5 and RNA polymerase I transcription termination factor (TTF-I), it has been 
speculated that the p19Arf–Mdm2–p53 and the RP–Mdm2–p53 pathways might be a single 
p19Arf–RP–Mdm2–p53 pathway, in which p19Arf activates p53 by inhibiting RP biosynthesis; 
thus, p19Arf deletion or Mdm2C305F mutation would result in similar consequences. Here, we 
generated mice with concurrent p19Arf deletion and Mdm2C305F mutation and investigated the 
compound mice for tumorigenesis in the absence and the presence of oncogenic c-Myc 
overexpression. In the absence of Eμ-myc transgene, the Mdm2C305F mutation did not elicit 
spontaneous tumors in mice, nor did it accelerate spontaneous tumors in mice with p19Arf 
deletion. In the presence of Eμ-myc transgene, however, Mdm2C305F mutation significantly 
accelerated p19Arf deletion-induced lymphomagenesis and promoted rapid metastasis. We found 
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that when p19Arf–Mdm2–p53 and RP–Mdm2–p53 pathways are independently disrupted, 
oncogenic c-Myc-induced p53 stabilization and activation is only partially attenuated. When both 
pathways are concurrently disrupted, however, c-Myc-induced p53 stabilization and activation are 
essentially obliterated. Thus, the p19Arf–Mdm2–p53 and the RP–Mdm2–p53 are non-redundant 
pathways possessing similar capabilities to activate p53 upon c-Myc overexpression.
INTRODUCTION
The Myc protein (c-Myc) is a helix-loop-helix leucine zipper transcriptional regulator, 
which forms specific DNA-binding heterodimers with the Max protein to control a variety of 
normal cellular functions.1 In addition, c-Myc facilitates the recruitment of Pol I (DNA 
polymerase I) to ribosomal DNA promoters,2 promotes the transcription of ribosomal 
proteins (RPs) by activating Pol II3 and activates Pol III-mediated transcription of 5S 
ribosomal RNA and transfer RNA.4 In addition, c-Myc is known to regulate ribosomal 
biogenesis through the transactivation of genes involved in ribosomal biogenesis, including 
RPs themselves.5 Increased c-Myc expression is frequently observed in human cancers and 
it can confer a growth advantage to cells by providing constitutive proliferative signals.6 
However, c-Myc overexpression may also initiate an endogenous apoptotic program,7 and 
through this function trigger a potent tumor surveillance response that effectively opposes 
hyperproliferation by killing those cells in which c-Myc levels exceed a safe threshold.8
The p53 transcription factor is a critical tumor suppressor, and when activated it triggers cell 
cycle arrest, differentiation, apoptosis and senescence. The TP53 gene is mutated in ~ 50% 
of all human tumors and is often referred to as the ‘guardian’ of the genome.9,10 p53 is 
primarily regulated by the E3 ubiquitin ligase murine double minute 2 (Mdm2), which binds 
to p53 to both block its transactivation domain and to promote its ubiquitination and 
degradation. However, p53 enhances Mdm2 transcription, thus forming an autoregulatory 
feedback loop.11
The tumor suppressor p19 alternative reading frame (p19Arf, p14Arf in human) is 
transcribed from an alternative reading frame of the INK4a/ARF locus. p19Arf physically 
binds to Mdm2, inhibiting its E3 ligase activity, thereby stabilizing and activating p53, 
which constitutes a p19Arf–Mdm2–p53 signaling pathway.12 Oncogenic c-Myc driven 
tumors receive a selective advantage from inactivation of the p19Arf–Mdm2–p53 pathway, 
diminishing its protective checkpoint function and accelerating normal cell progression to 
malignancy; this accelerated progression to malignancy is observed in Eμ-myc;p19Arf−/− 
transgenic mice, a model for Burkitt’s lymphoma, which die of lymphoma within a few 
weeks of birth.13
Previous evidence has demonstrated that several RPs such as RPL5, RPL11 and RPL23 
interact with Mdm2 to inhibit its E3 ligase function, thereby stabilizing and activating p53, 
suggesting an RP–Mdm2–p53 pathway.14 In vivo studies have established the physiological 
significance of the RP–Mdm2 interaction in responding to ribosomal stress to activate p53, 
providing evidence for a p53 checkpoint mediated by the RP–Mdm2 interaction, which is 
capable of monitoring the integrity of ribosome biogenesis.15 Furthermore, use of the Eμ-
myc transgenic mouse model, which constitutively expresses c-Myc in the B-cell lineage 
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and develops B-cell lymphoma at an early age,16 we have demonstrated that the RP–Mdm2–
p53 pathway, similar to the p19Arf–Mdm2–p53 pathway, plays a critical role in preventing 
oncogenic c-Myc-induced lymphomagenesis.15
Previous studies have shown that p19Arf can disturb ribosomal biogenesis by interacting 
with nucleophosmin (NPM/B23) and inhibiting pre-ribosomal RNA processing.17,18 More 
recently, it has been shown that p19Arf inhibits the function of RNA polymerase I 
transcription termination factor19 and DDX5 RNA helicase 20 by preventing their nucleolar 
localization, thereby inhibiting ribosomal biosynthesis. These studies raise an interesting 
question as to whether the p19Arf–Mdm2–p53 and the RP–Mdm2–p53 pathways might 
function in a linear manner as a p19Arf–RP–Mdm2–p53 pathway, where p19Arf 
additionally activates p53 by inhibiting RP biosynthesis. As such, p19Arf deletion or 
Mdm2C305F mutation, which disrupts RP–Mdm2 binding, would result in similar 
consequences in the context of c-Myc overexpression. To gain insight into the 
interrelationship and possible cooperative mechanisms between p19Arf–Mdm2–p53 and 
RP–Mdm2–p53 pathways, we studied tumorigenesis in mice with disruption of each 
pathway individually and in combination.
RESULTS
Mdm2C305F mutation does not accelerate p19Arf deletion caused spontaneous tumor 
development
Previous studies have shown that mice with homozygous deletion of p19Arf (p19Arf−/−) are 
predisposed to spontaneous tumor development,21 whereas mice with homozygous mutation 
of Mdm2C305F (henceforth referred to as Mdm2m/m), which prevents Mdm2 binding to 
RPL5 and RPL11,22 do not develop spontaneous tumors.15 Because p19Arf interacts with 
and inhibits NPM/B23,17,18 RNA polymerase I transcription termination factor19 and 
DDX5.20 As these factors are all involved in ribosomal biosynthesis we speculated that the 
p19Arf–Mdm2–p53 and the RP–Mdm2–p53 pathways might be functionally interconnected. 
We crossed p19Arf−/− and Mdm2m/m mice to generate double-heterozygous 
Mdm2+/m;p19Arf+/− mice and then intercrossed the Mdm2+/m; p19Arf+/− mice to generate 
Mdm2m/m;p19Arf−/− compound mice. Of the 186 pups born from intercross of the double-
heterozygotes, a predicted Mendelian inheritance was observed (Figure 1a, shown are only 
three genotypes for simplicity), indicating that concurrent disruption of p19Arf–Mdm2–p53 
and RP–Mdm2–p53 pathways does not affect embryogenesis and early development.
A survival study was carried out to examine the effect of concurrent p19Arf deletion and 
Mdm2C305F mutation on spontaneous tumor formation and lifespan in the mice. Consistent 
with previous studies, mice heterozygous for Mdm2C305F mutation (Mdm2+/m) and p19Arf 
deletion (p19Arf+/−) did not show any pathological or physiological changes. In addition, we 
did not observe any phenotypic changes in double-heterozygous Mdm2+/m; p19Arf+/− mice 
(data not shown). Consistent with previous reports,21 mice with homozygous deletion of 
p19Arf were predisposed to tumors, mostly lymphomas, and died shortly after the 
development of disease, resulting in a notably shorter lifespan compared to wild-type (WT) 
mice (Figure 1b). However, mice with homozygous Mdm2C305F mutation did not show 
observable differences in spontaneous tumor formation and lifespan from the WT 
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littermates. Interestingly, double-homozygous compound mice (Mdm2m/m;p19Arf−/−) did 
not show accelerated spontaneous tumor formation compared to mice with only p19Arf 
deletion, instead they displayed slightly decelerated tumor formation (Figure 1b; log-rank 
test P = 0.06); the reasons for the deceleration remain unclear. We have noticed that the 
mean latency for survival of the p19Arf−/− mice in our experiment is 16 months, 
significantly longer than the previous report of ~ 10 months.21 One likely reason for the 
difference is that our mice are in >99% pure C57BL6 background as compared to a mixed 
129svj/C57BL6 background in the previous study. It has been reported that C57BL6 mice 
are more resistant to spontaneous tumor formation than 129svj mice,23,24 and C57BL6 mice 
are more efficient in total leukocyte recruitment than 129svj mice,25 a function important in 
preventing lymphomagenesis.26
Concurrent disruption of the p19Arf–Mdm2–p53 and the RP–Mdm2-p53 pathways further 
accelerates oncogenic c-Myc-induced lymphomagenesis
To further investigate the consequence of disruption of the p19Arf–Mdm2–p53 and the RP–
Mdm2-p53 pathways on tumorigenesis, we generated Eμ-myc transgenic mice on Mdm2m/m 
and p19Arf−/− background individually and in combination, and compared their tumor-free 
survival time. Eμ-myc;WT mice died of pre-B/B-cell lymphoma with a mortality curve 
consistent with previous studies (Figure 2).13,16 The median survival for Eμ-myc; p19Arf+/− 
mice was 15.6 weeks, significantly shorter than Eμ-myc; WT mice (Figure 2a, P = 0.003), 
whereas the median survival for Eμ-myc;Mdm2+/m mice was not significantly different from 
that of Eμ-myc;WT mice (Figure 2b, P = 0.5). In contrast, homozygous Eμ-myc;p19Arf−/− 
and Eμ-myc;Mdm2m/m mice developed aggressive, rapid onset pre-B/B-cell lymphoma with 
a mean survival of 10.1 and 11.6 weeks, respectively (Figures 2a and b), indicating that 
p19Arf–Mdm2 and RP–Mdm2 binding function as barriers to oncogenic c-Myc-induced 
tumorigenesis.
To determine if the RP–Mdm2–p53 and p19Arf–Mdm2–p53 represent two parallel pathways 
or a single linear p19Arf–RP–Mdm2–p53 pathway against Eμ-myc transgene-induced 
lymphomas, we generated Eμ-myc;Mdm2m/m;p19Arf−/− compound mice and evaluated the 
impact of the double mutation on mouse survival. Remarkably, Eμ-
myc;Mdm2m/m;p19Arf−/− mice demonstrated a median survival of 7.6 weeks, evidently 
shorter than the lifespan observed in either Eμ-myc;Mdm2m/m or Eμ-myc;p19Arf−/− mice 
(Figure 2c). These data indicate that the p19Arf–Mdm2–p53 and the RP–Mdm2–p53 likely 
represent two independent signaling pathways possessing non-overlapping tumor 
suppression functions. We noticed that the mean survival of Eμ-myc;p19Arf−/−mice is 
significantly shorter than that of Eμ-myc;Mdm2m/m mice (10.1 vs 11.6 weeks; Figure 2c, P 
= 0.0001). This indicates that in addition to directly inhibiting Mdm2 and activating p53, 
p19Arf may also partially exert its function through the RP–Mdm2–p53 pathway by 
inhibiting ribosomal biogenesis.17,18
No significant difference in body weight gain was observed among the genotypes in the 
early stages of the mouse lifespan (Figure 2d). In later stages, however, the Eμ-
myc;p19Arf−/− mice grow larger, and the Eμ-myc;Mdm2m/m mice grow smaller than the Eμ-
myc;WT control mice. The reason for this discrepancy is unclear. In the final stages of their 
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life, the mice began to lose weight from cancerous cachexia, indicating that these Eμ-myc 
transgenic mice die of cachexia due to malignant tumor development.
Mdm2m/m;p19Arf−/− mice demonstrate accelerated c-Myc-induced tumorigenesis and 
metastasis
Splenomegaly is a common result of infiltration of lymphomas. Eμ-myc transgenic mice 
typically present a massive enlargement of the spleen.27 We measured the length of the 
spleens from mice at 9 weeks of age. As shown in Figure 3a, Eμ-myc;WT mice had an 
average spleen length of 1.6 cm, as compared to 1.1 cm spleen length in WT, non-transgenic 
mice. Both homozygous Mdm2C305F mutation and p19Arf deletion accelerated 
splenomegaly, with average spleen size increased in Eμ-myc;Mdm2m/m and Eμ-myc; 
p19Arf−/− transgenic mice to 2.4 and 2.5 cm, respectively. Compound mice harboring both 
Mdm2C305F mutation and p19Arf deletion demonstrated further accelerated splenomegaly, 
and the average spleen length of Eμ-myc;Mdm2m/m;p19Arf−/− mice was 3.8 cm at 9 weeks 
of age.
We next examined the invasive nature of Eμ-myc-induced lymphomas in the spleen, liver 
and kidney tissues isolated from 9-week-old mice. Spleen metastasis occurred earlier than 
other organs, and the structure of the spleens in mice harboring Eμ-myc transgene was 
already destroyed at this age. As shown in Figure 3b, expression of the Eμ-myc correlates 
with an increased number of small lymphocytes within the cords and sinuses, as well as 
some nodular aggregates surrounding a small vessel, indicative of spleen metastasis. The 
most significant metastasis was observed in the spleen of Eμ-myc;Mdm2m/m;p19Arf−/− 
compound mice. Similar to the spleen, lymphocyte infiltration in the liver can be seen in 
each of the Eμ-myc transgenic mice, specifically in the region surrounding the central veins. 
Not surprisingly, the most obvious liver metastasis was observed in Eμ-myc;Mdm2m/m; 
p19Arf−/− compound mice (Figure 3b). Kidney metastasis usually occurs in advanced or 
late-stage lymphomas, and metastatic tumor cells were detected as diffuse and disorganized 
cells infiltrating between the glomerulus and tubules.28 As shown in Figure 3b, in WT, Eμ-
myc;WT, Eμ-myc;Mdm2m/m and Eμ-myc; p19Arf−/− mice, kidneys revealed no discernible 
pathological phenotype, and lymphocyte infiltration is only obvious in the compound Eμ-
myc;Mdm2m/m;p19Arf−/− mice. Together, these data indicate that individually disrupting the 
p19Arf–Mdm2–p53 pathway by p19Arf deletion or the RP–Mdm2–p53 pathway by 
Mdm2C305F mutation augments the invasive nature of Eμ-myc-induced lymphoma. 
Simultaneous disruption of both pathways, as seen in Eμ-myc;Mdm2m/m;p19Arf−/− mice, 
leads to even more malignant and aggressive lymphomagenesis.
To determine if cells in Eμ-myc-expressing spleens retained their proliferative capacity, 
Ki-67 staining was used to assess cellular proliferation by immunohistochemistry. As shown 
in Figure 3c, in the absence of the Eμ-myc transgene Ki-67 expression was barely detectable 
in the spleen of 9-week-old WT mice (Ki-67 index 0.4). In Eμ-myc;WT mice, we detected 
increased numbers of Ki-67-positive cells (Ki-67 index 2.8); the number of Ki-67-positive 
cells was further increased in spleens from Eμ-myc;Mdm2m/m and Eμ-myc;p19Arf−/− mice 
(Ki-67 index 12.2 and 14.6, respectively). In spleens of Eμ-myc;Mdm2m/m;p19Arf−/− 
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compound mice the number of Ki-67-positive cells was even further increased (Ki-67 index 
53.9).
To examine apoptosis in the spleen tumors of the transgenic mice, TUNEL (terminal 
deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling) 
immunohistochemical analysis was performed. Representative pictures of TUNEL-stained 
sections are shown in Figure 3d. Consistent with previous studies that Eμ-myc induces 
apoptosis in transgenic spleens,29 in spleens of 9-week-old Eμ-myc;WT, Eμ-myc;Mdm2m/m 
and Eμ-myc;p19Arf−/−mice, we detected high levels of TUNEL-positive apoptotic cells 
(14.6, 13.6, and 14.4%, respectively). However, in spleens of Eμ-myc;Mdm2m/m;p19Arf−/− 
compound mice the number of TUNEL-positive apoptotic cells decrease to 6.2%.
Local invasion and distant metastasis of lymphomas are commonly observed in Eμ-myc 
transgenic mice; we therefore analyzed liver tissues from individual mice for signs of 
metastasis. Eμ-myc transgenic mice were monitored for signs of moribund conditions,30 and 
moribund mice were killed and the livers were collected and examined for sign of 
metastasis. Tumors were detected in the livers of Eμ-myc;WT transgenic mice at an average 
age of 22 weeks (Figure 3e). In contrast, tumor onset in the liver was detected much earlier 
in Eμ-myc;Mdm2m/m, Eμ-myc;p19Arf−/−and Eμ-myc;Mdm2m/m;p19Arf−/− mice, with 
progressively shorter time of onset at 13, 11 and 9 weeks, respectively (Figure 3e). These 
results demonstrate that individually the Mdm2C305F mutation and p19Arf deletion promote 
local invasion and distant metastasis of Eμ-myc-induced lymphomas, with p19Arf deletion 
having a stronger effect than Mdm2C305F mutation, which is consistent with the shorter 
lifespan of the Eμ-myc;p19Arf−/− mice compared to the Eμ-myc;Mdm2m/m mice (Figure 
2c). Concurrent Mdm2C305F mutation and p19Arf deletion further accelerates the 
aggressiveness of the lymphoma, resulting in an even shorter lifespan, consistent with the 
notion that the p19Arf–Mdm2–p53 and the RP–Mdm2–p53 represent two non-redundant, 
independent pathways for tumor suppression.
The p19Arf–Mdm2–p53 and the RP–Mdm2–p53 pathways function independently in 
oncogenic c-Myc-induced p53 activation
Oncogene c-Myc induces p53 to promote apoptosis, functioning as part of a major tumor 
suppression network. Because Eμ-myc-induced lymphomagenesis in mice can be further 
accelerated by concurrent disruption of the p19Arf–Mdm2–p53 and the RP–Mdm2–p53 
pathways compared to disruption of either pathway alone, we reasoned that the two 
pathways could each individually be required for oncogenic c-Myc-induced p53 activation. 
To test this hypothesis, spleen extracts from 4-week-old, non-tumor-bearing Eμ-myc;WT, 
Eμ-myc;Mdm2m/m, Eμ-myc;p19Arf−/− and Eμ-myc;Mdm2m/m;p19Arf−/− transgenic mice, 
as well as from their non-transgenic counterparts, were analyzed for p53 expression. At this 
age the spleens harboring the Eμ-myc transgene are moderately hyperplastic, but still 
comparable in size and morphology to the spleens of non-transgenic mice (data not shown). 
The Eμ-myc transgene markedly induced p53 protein expression in WT mouse spleens 
(Figure 4a, lane 2), which is accompanied by increased expression of p19Arf, RPL5 and 
RPL11, all of which are known transcriptional targets of c-Myc.31,32 The Eμ-myc transgene 
also induced p53 expression in Eμ-myc;Mdm2m/m and Eμ-myc;p19Arf−/− spleens to a 
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similar level, although slightly lower than what is detected in Eμ-myc;WT spleens (Figure 
4a, compare lanes 2, 4 and 6). Remarkably, p53 induction was not observed in Eμ-
myc;Mdm2m/m;p19Arf−/− compound mouse spleens (Figure 4a, lane 8). These data 
demonstrate that individual disruption of the p19Arf–Mdm2–p53 pathway by p19Arf 
deletion or the RP–Mdm2–p53 pathway by Mdm2C305F mutation does not block c-Myc 
induction of p53, while simultaneous disruption of both pathways blocks c-Myc-induced 
p53 expression. To ascertain whether these observations are Eμ-myc transgene specific, we 
infected early passage WT, Mdm2m/m, p19Arf−/− and Mdm2m/m; p19Arf−/− mouse embryo 
fibroblast (MEF) cells with retrovirus-expressing pBabe–c-Myc to determine if transient 
expression of c-Myc gives rise to similar results. Consistent with observations made in 
mouse spleens, transient expression of pBabe–c-Myc resulted in p53 induction in WT, 
Mdm2m/m and p19Arf−/− MEFs, but not in Mdm2m/m;p19Arf−/− MEFs (Figure 4b). 
Furthermore, the increased protein level of p53 was directly correlated with its 
transcriptional activity, indicated by S-18 phosphorylation of p53 in the spleens (p21 was 
undetectable in spleens; Figure 4a), and increased p21 protein level in pBabe–c-Myc 
infected MEFs (Figure 4b).
To corroborate the protein analysis, we carried out quantitative RT–PCR to further examine 
p53 activity in 4-week-old, non-tumor-bearing Eμ-myc;WT, Eμ-myc;Mdm2m/m, Eμ-
myc;p19Arf−/− and Eμ-myc;Mdm2m/m;p19Arf−/− mouse spleens and in spleens from their 
non-transgenic counterparts. We chose p53 targets involved in cell cycle regulation (p21), 
apoptosis induction (Bax and Apaf1) and metabolism regulation (TIGAR) to determine 
whether p53 is activated universally for its target genes. Induction of each of these p53 target 
genes was evident in Eμ-myc;WT, Eμ-myc;Mdm2m/m and Eμ-myc;p19Arf−/− mouse 
spleens, but not in Eμ-myc;Mdm2m/m;p19Arf−/− mouse spleens (Figures 4c and f), 
consistent with protein analysis. Together, our data indicate that not only can the p19Arf–
Mdm2–p53 and the RP–Mdm2–p53 pathways be independently responsible for oncogenic 
c-Myc induction of p53, but also that the two pathways together contribute to most if not all 
p53 tumor suppressor response to c-Myc activation. Disabling both pathways results in 
undetectable p53 activation by oncogenic c-Myc overexpression.
DISCUSSION
The importance of p19Arf–Mdm2–p53 and RP–Mdm2–p53 signaling pathways in 
defending against oncogenic c-Myc-induced tumorigenesis is well established, and studies 
have shown that disruption of each of the two pathways by deletion or mutation accelerates 
the progression of malignancy in c-Myc-expressing mice.13,15 In this study, we generated 
and analyzed mice with concurrent disruption of these two pathways and compared p53 
activity and tumorigenesis to mice with disruption of each pathway alone. The significance 
and implications of these findings are discussed below.
The p19Arf–Mdm2–p53 and the RP–Mdm2–p53 signaling pathways act independently in 
oncogenic c-MYC-induced p53 activation
The generation of Mdm2m/m mice has allowed for a detailed in vivo characterization of the 
role of RP–Mdm2 binding in p53 activation and tumor suppression. Unlike the disruption of 
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the p19Arf–Mdm2–p53 pathway by p19Arf deletion, which results in spontaneous tumor 
development,33 disruption of the RP–Mdm2–p53 pathway by Mdm2C305F mutation does not 
result in spontaneous tumor development.15 The different tumorigenic potential between the 
two mouse models could be a result of the nature of the two pathways in each of the mouse 
models. In the p19Arf−/− mice the entire p19Arf gene is deleted, disrupting p19Arf–Mdm2 
binding as well as all other p19Arf-related functions; in the Mdm2m/m mice, however, the 
single-point mutation in the Mdm2 is less disruptive, and while Mdm2C305F mutant protein 
cannot properly bind to RPL5/RPL11, it retains binding to RPL23,22 thus only reducing but 
not eliminating the functions of this pathway. Alternatively, it is conceivable that the 
p19Arf–Mdm2–p53 pathway primarily responds to deregulated oncogenes, which inflict a 
great risk of tumor formation if left unchecked, whereas the RP–Mdm2–p53 pathway may 
primarily respond to deregulated ribosome biosynthesis, which may play a lesser role in 
promoting cancerous growth.
In addition, it has been shown that p19Arf binds to and inhibits the ability of c-Myc to 
induce hyperproliferation and transformation through34,35 indicating loss of p19Arf could 
contribute to c-Myc-induced tumorigenesis by at least two mechanisms. Similarly, it has 
been shown that RPL11 binds to c-Myc and inhibits its transcriptional activity36 and that 
RPL5, cooperatively with RPL11, guides the RNA-induced silencing complex to c-Myc 
mRNA and mediates the degradation of c-Myc mRNA.37 These studies in combination with 
our results point to the importance of both p19Arf and RP signaling in c-Myc-induced 
lymphomagenesis. Our results agree with the notion that Eμ-myc-induced lymphomagenesis 
can be accelerated by disruption of negative regulators of c-Myc in each pathway in addition 
to disruption of p53 activation.
Our study also addresses the degree of cooperation between the p19Arf–Mdm2–p53 and 
RP–Mdm2–p53 pathways in p53 response to oncogenic c-Myc overexpression. When 
Mdm2C305F mutation or p19Arf deletion occur individually, c-Myc over-expression still 
elicits sufficient p53 response; however, when Mdm2C305F mutation and p19Arf deletion 
occur concurrently, c-Myc overexpression does not elicit p53 activation. Given the role of 
oncogenic c-Myc in promoting aberrant ribosomal biogenesis, the p19Arf-independent, c-
Myc-mediated induction of p53 in the p19Arf−/− cells is conceivably dependent on c-Myc-
induced overexpression of RPs, which activate p53 through interaction with Mdm2.15 
Conversely, activation of p53 by c-Myc in Mdm2m/m mice is p19Arf dependent, as the 
p19Arf–Mdm2–p53 pathway remains intact in mice and c-Myc can induce p19Arf 
expression (Figure 4). Our data suggest that p53 responds to c-Myc overexpression via two 
independent signaling pathways: p19Arf–Mdm2–p53 and RP–Mdm2–p53. Each pathway 
conveys a share of c-Myc signaling to p53, and disruption of either one reduces, but not 
eliminates, p53 response to c-Myc overexpression. Consequently, disrupting either pathway 
will accelerate c-Myc-induced tumor formation, as illustrated by shortened survival times of 
Eμ-Myc;Mdm2m/m and Eμ-Myc;p19Arf−/− mice compared to Eμ-myc;WT mice. Disrupting 
both pathways further accelerates c-Myc-induced tumorigenesis, as illustrated by the 
comparatively shorter tumor-free lifespan of Eμ-Myc;Mdm2m/m; p19Arf−/− compound mice. 
Our data support a model in which the RP–Mdm2–p53 and p19Arf–Mdm2–p53 pathways 
represent two non-redundant, parallel mechanisms for p53 induction (Figure 5). Intriguingly, 
the lack of detectable p53 activation in the Eμ-myc; Mdm2m/m;p19Arf−/− compound mice 
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implies that other active mechanisms transmitting oncogenic c-Myc signal to p53 either may 
not exist or be insufficient to raise p53 to a detectable level.
The p19Arf–Mdm2 connection mediates a p53-dependent checkpoint in response to a broad 
range of oncogenic insults, including elevated expression of c-Myc, E2F1, Ras, E1A and 
BCR-ABL. However, the RP–Mdm2 connection provides evidence for a prevailing in vivo 
checkpoint for the integrity of ribosome biogenesis to invoke p53 response if the process 
goes awry. Given that overexpression of many oncogenes promotes fast growth and 
proliferation, which inevitably requires accelerated ribosomal biogenesis it is reasonable to 
speculate that the RP–Mdm2–p53 signaling pathway, in addition to responding to c-Myc 
overexpression, may also respond to other deregulated oncogenes that cause superfluous 
ribosomal biogenesis. The Mdm2m/m mouse model provides a convenient tool to investigate 
whether the RP–Mdm2–p53 pathway, as in the case of the p19Arf–Mdm2–p53 pathway, 
functions generally in oncogenic signaling surveillance, capable of responding to a broad 
range of deregulated oncogenes, or is only specific to oncogenic c-Myc.
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in agreement with the ethical standards according to the 
Declaration of Helsinki, national and international guidelines, and has been approved by the 
authors’ institutional review board.
Cell culture
Primary MEFs were isolated on embryonic (E) day 13.5 and grown in a 37 °C incubator 
with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) supplied with 10% fetal 
bovine serum and penicillin-streptomycin. For retroviral infections, WT, Mdm2m/m, 
p19Arf−/− and Mdm2m/m;p19Arf−/− MEFs were infected with retroviruses expressing c-
MYC or pBabe control vector, and selected with puromycin (2.5 μg/ml) for 3 days. Infected 
MEFs were then allowed to recover for 48 h and harvested for analysis. MEFs at passage 4 
were used for growth curves, western blotting and other analyses.
Mouse experiments
Mice were bred and maintained strictly under protocol (13-044) approved by the 
Institutional Animal Care and Use Committee in the University of North Carolina Animal 
Care Facility. Mdm2m/m females were bred with p19Arf−/− males to obtain 
Mdm2+/m;p19Arf+/− offspring, which were then crossed with Mdm2+/m;p19Arf+/− mice to 
obtain Mdm2m/m;p19Arf−/− compound mice. For c-MYC-mediated tumorigenesis study, 
Mdm2m/m; p19Arf−/− females were bred with Eμ-myc transgenic males to obtain Eμ-
myc;Mdm2+/m;p19Arf+/− offspring, which were then crossed with Mdm2+/m;p19Arf+/− 
mice to obtain Eμ-myc;Mdm2m/m;p19Arf−/− compound mice. Eμ-myc mice were purchased 
from Jackson Laboratory (002728). For survival studies, mice were palpated regularly for 
early signs of inguinal lymph node enlargement and monitored for tumor progression and 
signs of morbidity. Moribund mice were humanely euthanized. Mouse tumors and organs 
were fixed in formalin for histopathology and snap frozen for protein and RNA extraction.
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For western blot, MEFs were lysed with 0.5% (Tergitol, Sigma, St Louis, MO, USA) NP-40 
lysis buffer. For mouse tissue protein extraction, tissue from the spleen, thymus and 
lymphomas was ground by mortar and pestle with liquid N2, and protein was extracted with 
0.5% NP-40 lysis buffer. Mouse monoclonal anti-Mdm2 (2A10, Calbiochem, Billerica, MA, 
USA), p53 (NCL-505, Novocastra, Buffalo Grove, IL, USA), actin (MAB1501, Chemicon 
International, Billerica, MA, USA), goat polyclonal anti-p53 (FL-393, Santa Cruz 
Biotechnology, Dallas, TX, USA) and rat monoclonal anti-p19Arf (5-C3-1, Santa Cruz 
Biotechnology) antibodies were purchased commercially. Rabbit polyclonal antibodies to 
p21 were gifts from Dr Yue Xiong (UNC-Chapel Hill). Rabbit polyclonal antibodies to L5 
and L11 were made in house as previously described.22
Measurement of mouse tissue
Spleens, kidneys and livers from 9-week-old mice were excised, photographed and weighed. 
All procedures involving mice were carried out according to protocol 13-044, approved by 
the University of North Carolina Institutional Animal Care and Use Committee.
Histopathology
Animals were autopsied and all tissues were examined regardless of their pathological 
status. Spleen, kidney and liver tissue from Eμ-myc;WT, Myc; Mdm2m/m, Eμ-
myc;p19Arf−/− and Eμ-myc;Mdm2m/m;p19Arf−/− transgenic mice, as well as tissue from 
non-transgenic counterparts were fixed overnight in 10% phosphate-buffered formalin and 
then transferred to 70% ethanol. Samples were sent to the UNC Histology Core Facility for 
paraffin embedding. Paraffin blocks were sectioned at 5-mm intervals for successive layers 
and stained with H&E for histopathology examination.
Proliferation analysis
Ki-67 immunohistochemical staining of mouse spleen samples was used to detect 
proliferating cells. Antigen retrieval for antibody on formalin-fixed paraffin sections was 
carried out by boiling paraffin samples in citrate buffer (pH 6.0) for 15 min. Endogenous 
peroxidase activity was quenched by incubation in 3% H2O2 in methanol for 10 min. 
Antibody detection was carried out with purified mouse anti Ki-67 primary antibody (BD 
Pharmingen, San Diego, CA, USA) and biotin-conjugated anti-mouse secondary antibody 
(Vector Laboratories, Burlingame, CA, USA). Ki-67-expressed cells were stained brown 
color by biotin-peroxidase kit (VECTASTAIN Elite, Vector Laboratories). The ratio of 
positively stained cells to total cells was calculated. Student’s t-test (P<0.05 was considered 
significant) was used to compare the differences in proliferation levels between the different 
mouse genotypes.
Apoptosis analysis
Levels of apoptosis in mouse spleen sections were assessed by the TUNEL assay according 
to instructions (ApopTag Peroxidase in situ kit, S7100, Millipore, Temecula, CA, USA).
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Total RNA was isolated using an RNeasy kit (74104, Qiagen, Hilden, Germany) and cDNA 
was synthesized using SuperScript III (18080400, Life Technologies, Waltham, MA, USA). 
qRT–PCR was performed with SYBR green master mix using the 7900HT fast real-time 
PCR system (Applied Biosystems, Waltham, MA, USA) according to manufacturers’ 
instructions. Data were collected and exported with SDS 2.2.2 software (Applied 
Biosystems). Relative expression was calculated using actin as an internal control as 
indicated. Primers used were as follows: p21, 5′-CCTGGTGATGTCCGACCTG-3′ and 5′-









Statistical analysis was carried out using GraphPad Prism 5 Software (Graph-Pad Software, 
San Diego, CA, USA). Kaplan–Meier survival curve was carried out to assess lifespan.
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Disruption of the p19Arf–Mdm2–p53 pathway, but not the RP–Mdm2–p53 pathway, results 
in spontaneous tumor development. (a) The image shown are expected and observed birth 
ratios from a total of 186 mice obtained from Mdm2+/m;p19Arf+/− mice intercrosses (shown 
only three genotypes for simplicity). (b) Kaplan–Meier survival curves for WT, Mdm2m/m, 
p19Arf−/− and Mdm2m/m; p19Arf−/− mice are shown. Two to five mice of the same gender 
were housed in each cage, and the mice were observed over a 24-month period. Median 
survival time of p19Arf−/− and Mdm2m/m;p19Arf−/− mice was 16 and 19 months, 
respectively. There was no significant difference between survival of p19Arf−/− and 
Mdm2m/m;p19Arf−/− mice (analyzed by log-rank test, P = 0.06).
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c-Myc-induced lymphomagenesis is accelerated by Mdm2m/m or p19Arf−/− mutations, and 
is further accelerated by concurrent Mdm2m/m;p19Arf−/− mutation. (a) Survival of Eμ-myc 
transgenic p19Arf deletion mice. The median survival time for each genotype was as 
follows: Eμ-myc;WT (20.7 weeks), Eμ-myc;p19Arf+/− (15.6 weeks) and Eμ-
myc;p19Arf−/− (10.1 weeks). Log-rank test, P = 0.003 between Eμ-myc;WT and Eμ-
myc;p19Arf+/− mice; P<0.0001 between Eμ-myc;p19Arf+/− and Eμ-myc;p19Arf−/− mice. 
(b) Survival of Eμ-myc transgenic Mdm2C305F mutation mice. The median survival times 
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were as follows: Eμ-myc;WT (20.7 weeks), Eμ-myc;Mdm2+/m (17.9 weeks) and Eμ-
myc;Mdm2m/m (11.6 weeks). Log-rank test, P = 0.5 between Eμ-myc;WT and Eμ-
myc;Mdm2+/m mice; P<0.0001 between Eμ-myc;Mdm2+/m and Eμ-myc;Mdm2m/m mice. (c) 
Survival of Eμ-myc;WT (20.7 weeks), Eμ-myc;Mdm2m/m (11.6 weeks), Eμ-
myc;p19Arf−/− (10.1 weeks) and Eμ-myc;Mdm2m/m;p19Arf−/− (7.6 weeks) mice. Log-rank 
test, P = 0.0001 between Eμ-myc; Mdm2m/m and Eμ-myc;p19Arf−/− mice; P<0.0001 
between Eμ-myc; p19Arf−/− and Eμ-myc;Mdm2m/m;p19Arf−/− mice. (d) Body weight of 
mice expressing Eμ-myc.
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Mdm2m/m;p19Arf−/− compound mice demonstrate accelerated c-Myc-induced tumorigenesis 
and metastasis. (a) Length of 9-week-old (±3 days) mouse spleens of WT (n = 5), Eμ-
myc;WT (n = 5), Eμ-myc;Mdm2m/m (n = 5), Eμ-myc;p19Arf−/− (n = 5) and Eμ-
myc;Mdm2m/m;p19Arf−/−(n = 5) mice. Spleen length was measured and the median lengths 
were as follows: WT (1.14 cm), Eμ-myc;WT (1.56 cm), Eμ-myc;Mdm2m/m (2.36 cm), Eμ-
myc;p19Arf−/− (2.54 cm) and Eμ-myc;Mdm2m/m;p19Arf−/− (3.82 cm). Data are represented 
as mean ± s.e.m. and were analyzed by Student’s t-test. ***P<0.001; **P<0.01. (b) 
Hematoxylin and eosin (H&E) staining of spleen, liver and kidney tissues. WT mouse spleen 
serves as a positive control for normal spleen structure. Structure of spleens from Eμ-myc 
transgenic mice was destroyed by lymphocyte infiltration. Lymphocyte infiltration was 
observed as dark blue staining. The malignant cells are dispersed and the nuclei are larger 
than normal lymphocytes. Aggregates of small lymphocytes are observed in the livers and 
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kidneys of Eμ-myc transgenic mice. Scale bar, 400 μm. (c) Representative Ki-67 staining of 
spleens from different genotypes of 9-week-old mice, as indicated. Brown staining indicates 
Ki-67-positive proliferating cells. Scale bar, 100 μm. The Ki-67 index (calculated as the 
percentage of Ki-67-positive tumor cells vs total cells in the view field from at least five 
randomly chosen fields along the edge of spleens) for the genotypes assayed are indicated in 
parentheses: WT (0.4), Eμ-myc; WT (2.8), Eμ-myc;Mdm2m/m (12.2), Eμ-
myc;p19Arf−/− (14.6 ) and Eμ-myc;Mdm2m/m;p19Arf−/− (53.9) mice. Data are represented 
as mean ± s.e.m. ***P<0.001. (d) Representative TUNEL staining of spleens from different 
genotypes of 9-week-old mice. The percentage of TUNEL-positive cells in the view field 
was calculated from at least five randomly chosen fields along the edge of spleens and is 
indicated in parentheses: WT (8.4%), Eμ-myc;WT (14.6%), Eμ-myc;Mdm2m/m (13.6%), 
Eμ-myc;p19Arf−/− (14.4%) and Eμ-myc;Mdm2m/m;p19Arf−/− (6.2%). Data are represented 
as mean ± s.e.m. ***P<0.001; **P<0.01. Scale bar, 200 μm. (e) H&E staining of livers from 
different genotypes of similar metastasis stage. Mouse livers were collected at the time of 
death. Time of metastasis is indicated in parentheses: Eμ-Myc;WT (22 weeks), Eμ-
Myc;Mdm2m/m (12.5 weeks), Eμ-Myc;p19Arf−/− (11 weeks) and Eμ-
Myc;Mdm2m/m;p19Arf−/− (9 weeks). Scale bar, 400 μm.
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The RP–Mdm2–p53 and p19Arf–Mdm2–p53 signaling pathways function independently in 
oncogenic c-MYC induction of p53. (a) Extracts from spleens of 4-week-old, non-tumor-
bearing Eμ-myc;WT, Eμ-myc;Mdm2m/m, Eμ-myc;p19Arf−/− and Eμ-
myc;Mdm2m/m;p19Arf−/− transgenic mice and spleens from their non-transgenic 
counterparts were analyzed by western blot. (b) Early passage WT, Mdm2m/m, p19Arf−/− 
and Mdm2m/m;p19Arf−/− MEFs were infected with retrovirus expressing either pBabe 
vector (−) or pBabe–c-Myc (+), selected by puromycin for 3 days, then allowed to recover 
for 48 h before harvesting for western blot analysis. (c–f) mRNA levels of p21 (c), Bax (d), 
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Apaf1 (e) and TIGAR (f) in spleens of 4-week-old, non-tumor-bearing Eμ-myc;WT, Eμ-
myc;Mdm2m/m, Eμ-myc;p19Arf−/− and Eμ-myc;Mdm2m/m;p19Arf−/− transgenic mice, and 
in spleens of their non-transgenic counterparts, analyzed by quantitative RT–PCR. All 
samples were analyzed in triplicate. Data are means ± s.d. calculated from three independent 
experiments and normalized to actin. Data are represented as mean ± s.e.m., and were 
analyzed by Student’s t-test. *P<0.1; **P<0.01; ***P<0.001; and NS indicates no 
significant difference.
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A model depicting non-overlapping functions of the p19Arf–Mdm2–p53 and the RP–
Mdm2–p53 pathways in oncogenic c-Myc-induced p53 activation. In WT cells, oncogenic c-
Myc signal engages with both p19Arf–Mdm2–p53 and RP–Mdm2–p53 pathways, resulting 
in maximum Mdm2 inhibition and p53 stabilization and activation (first panel). In cells with 
p19Arf deletion (second panel) or Mdm2C305F mutation (third panel), c-Myc signal engages 
with one of the remaining pathways to induce p53, but to a lesser degree. In cells with 
concurrent p19Arf deletion and Mdm2C305F mutation, c-Myc overexpression cannot induce 
p53 to detectable levels (fourth panel).
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